You may receive up to 2 years of pembrolizumab. You will only receive T-cells, chemotherapy, and IL-2 one time (while you are hospitalized). You will no longer be able to take the study drugs if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions.